H. Lundbeck A/S (VIE:LUNA)
4.670
-0.140 (-2.91%)
At close: Sep 26, 2025
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2005 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2005 - 2019 |
Rexulti | 5.20B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Rexulti Growth | 14.96% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Brintellix/Trintellix | 4.85B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Brintellix/Trintellix Growth | 12.10% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Abilify Long-acting Injectable Franchise | 3.50B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Abilify Long-acting Injectable Franchise Growth | 9.95% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Pharmaceuticals | 3.18B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Pharmaceuticals Growth | -1.97% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Vyepti | 2.91B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Vyepti Growth | 71.42% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Cipralex/Lexapro | 2.05B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Cipralex/Lexapro Growth | -4.07% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Reconciling Items | 366.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Reconciling Items Growth | 11.93% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Exceptional Items | -52.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Exceptional Items Growth | -137.96% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Sabril | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Sabril Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Onfi | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Onfi Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Northera | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Northera Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Reconciling Items | 366.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Reconciling Items Growth | 11.93% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Exceptional Items | -52.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Exceptional Items Growth | -137.96% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2005 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2005 - 2019 |
Reconciling Items | 366.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Reconciling Items Growth | 11.93% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Exceptional Items | -52.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Exceptional Items Growth | -137.96% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
United States | 11.33B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
United States Growth | 15.22% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
International | 5.22B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
International Growth | 4.57% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Europe | 5.13B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Europe Growth | 11.21% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Reconciling Items | 366.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Reconciling Items Growth | 11.93% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Denmark | 15.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Denmark Growth | 7.14% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Exceptional Items | -52.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Exceptional Items Growth | -137.96% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
North America | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
North America Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|